Epigenetically altered miR-193b targets cyclin D1 in prostate cancer

Cancer Medicine

Volumn 4, Issue 9, 2015, Pages 1417-1425

  Kaukoniemi, Kirsi M ^a,b   Rauhala, Hanna E ^a   Scaravilli, Mauro ^a,b   Latonen, Leena ^a,b   Annala, Matti ^a   Vessella, Robert L ^c   Nykter, Matti ^a   Tammela, Teuvo L J ^a   Visakorpi, Tapio ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclin D1; Micro RNA; Prostate cancer

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; MICRORNA; MICRORNA 193B; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MESSENGER RNA; MIRN193 MICRORNA, HUMAN;

22RV1 CELL; 3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CCND1 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DU145 CELL; EPIGENETICS; GENE OVEREXPRESSION; GENE TARGETING; GROWTH RETARDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PC 3 CELL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; RNA METHYLATION; VCAP CELL; CANCER GRADING; CANCER STAGING; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR RECURRENCE;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CYCLIN D1; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER;

EID: 84958955869     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.486     Document Type: Article

References (36)

1. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69-90.
2. Knudsen, K. E., and W. K. Kelly. 2011. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert. Rev. Endocrinol. Metab. 6:483-493.
3. Schroder, F. H., J. Hugosson, M. J. Roobol, T. L. Tammela, M. Zappa, V. Nelen, et al. 2014. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027-2035.
4. Catto, J. W., A. Alcaraz, A. S. Bjartell, R. De Vere White, C. P. Evans, S. Fussel, et al. 2011. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 59:671-681.
5. Lee, C., and V. Ambros. 2001. An extensive class of small RNAs in Caenorhabditis elegans. Science 294:862-864.
6. Lagos-Quintana, M., R. Rauhut, W. Lendeckel, and T. Tuschl. 2001. Identification of novel genes coding for small expressed RNAs. Science 294:853-858.
7. Di Leva, G., and C. M. Croce. 2010. Roles of small RNAs in tumor formation. Trends Mol. Med. 16:257-267.
8. Rauhala, H. E., S. E. Jalava, J. Isotalo, H. Bracken, S. Lehmusvaara, T. L. Tammela, et al. 2010. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int. J. Cancer 127:1363-1372.
9. Li, X. F., P. J. Yan, and Z. M. Shao. 2009. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 28:3937-3948.
10. Xu, C., S. Liu, H. Fu, S. Li, Y. Tie, J. Zhu, et al. 2010. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur. J. Cancer 46:2828-2836.
11. Chen, J., H. E. Feilotter, G. C. Pare, X. Zhang, J. G. Pemberton, C. Garady, et al. 2010. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 176:2520-2529.
12. Chen, J., X. Zhang, C. Lentz, M. Abi-Daoud, G. C. Pare, X. Yang, et al. 2011. miR-193b regulates Mcl-1 in melanoma. Am. J. Pathol. 179:2162-2168.
13. Gao, X. N., J. Lin, L. Gao, Y. H. Li, L. L. Wang, and L. Yu. 2011. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk. Res. 35:1226-1232.
14. Ikeda, Y., E. Tanji, N. Makino, S. Kawata, and T. Furukawa. 2012. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol. Cancer Res. 10:259-269.
15. Leivonen, S. K., A. Rokka, P. Ostling, P. Kohonen, G. L. Corthals, O. Kallioniemi, et al. 2011. Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. Mol. Cell Proteomics 10:M110.005322.
16. Hu, H., S. Li, J. Liu, and B. Ni. 2012. MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 44:424-430.
17. Musgrove, E. A., C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland. 2011. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11:558-572.
18. Knudsen, K. E., W. K. Cavenee, and K. C. Arden. 1999. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 59:2297-2301.
19. Reutens, A. T., M. Fu, C. Wang, C. Albanese, M. J. McPhaul, Z. Sun, et al. 2001. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol. 15:797-811.
20. Petre, C. E., Y. B. Wetherill, M. Danielsen, and K. E. Knudsen. 2002. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J. Biol. Chem. 277:2207-2215.
21. Jalava, S. E., K. P. Porkka, H. E. Rauhala, J. Isotalo, T. L. Tammela, and T. Visakorpi. 2009. TCEB1 promotes invasion of prostate cancer cells. Int. J. Cancer 124:95-102.
22. Urbanucci, A., B. Sahu, J. Seppala, A. Larjo, L. M. Latonen, K. K. Waltering, et al. 2012. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31:2153-2163.
23. Leinonen, K. A., T. T. Tolonen, H. Bracken, U. H. Stenman, T. L. Tammela, O. R. Saramaki, et al. 2010. Association of SPINK1 expression and TMPRSS2: ERG fusion with prognosis in endocrine-treated prostate cancer. Clin. Cancer Res. 16:2845-2851.
24. Tuominen, V. J., and J. Isola. 2009. The application of JPEG2000 in virtual microscopy. J. Digit. Imaging 22:250-258.
25. Tuominen, V. J., and J. Isola. 2010. Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J. Digit. Imaging 23:454-462.
26. Tuominen, V. J., S. Ruotoistenmaki, A. Viitanen, M. Jumppanen, and J. Isola. 2010. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12:R56.
27. Drobnjak, M., I. Osman, H. I. Scher, M. Fazzari, and C. Cordon-Cardo. 2000. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res. 6:1891-1895.
28. Murphy, C., M. McGurk, J. Pettigrew, A. Santinelli, R. Mazzucchelli, P. G. Johnston, et al. 2005. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin. Cancer Res. 11:4117-4127.
29. Aaltomaa, S., M. Eskelinen, and P. Lipponen. 1999. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 38:175-182.
30. Kallakury, B. V., C. E. Sheehan, R. A. Ambros, H. A. Fisher, R. P. Jr Kaufman, and J. S. Ross. 1997. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80:753-763.
31. Comstock, C. E., M. P. Revelo, C. R. Buncher, and K. E. Knudsen. 2007. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br. J. Cancer 96:970-979.
32. Bonci, D., V. Coppola, M. Musumeci, A. Addario, R. Giuffrida, L. Memeo, et al. 2008. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14:1271-1277.
33. Porkka, K. P., E. L. Ogg, O. R. Saramaki, R. L. Vessella, H. Pukkila, H. Lahdesmaki, et al. 2011. The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosom. Cancer 50:499-509.
34. Xie, C., X. H. Jiang, J. T. Zhang, T. T. Sun, J. D. Dong, A. J. Sanders, et al. 2013. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene 32:2282-2291, 2291.e1-7.
35. Helenius, M. A., K. J. Savinainen, G. S. Bova, and T. Visakorpi. 2006. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. BJU Int. 97:404-409.
36. Prensner, J. R., M. K. Iyer, O. A. Balbin, S. M. Dhanasekaran, Q. Cao, J. C. Brenner, et al. 2011. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29:742-749.